Beyond Meat Posts Mixed Results; CRISPR Therapeutics Tops Estimates
- August 08th, 2023
- 369 views
Beyond Meat, Inc. (Nasdaq: BYND) has reported a second-quarter 2023 loss of $0.83 per share, slightly better than the consensus estimated loss of $0.86 per share. However, quarterly revenues of $102.10 million fell short of the analysts' projected $108.40 million mark.
The company has revised its full-year 2023 outlook, forecasting net revenues within the range of approximately $360 million to $380 million, down from the prior projection of $375 million to $415 million. The consensus estimate for the period stands at $388.04 million in revenue.
$BYND was trading at $13.49 in after-hours, showing a decrease of $1.79 (-11.71%)
In other news, CRISPR Therapeutics AG (Nasdaq: CRSP) has announced its second-quarter 2023 financial results, revealing a loss of $0.98 per share and revenues of $70.0 million. These figures surpassed market consensus estimates, which had anticipated a loss of $2.12 per share on revenue of $1.71 million.
In after-hours, $CRSP was trading at $49.10, up $0.76 (+1.57%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP Football League Provides Development and Opportunity for Athletes Pursuing the Next Level
March 20th, 2026March 19th, 2026How High School Graduates Can Kickstart Their Football Career
March 18th, 2026
Member Login